Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials

Hypoglycaemia and the fear of hypoglycaemia are barriers to achieving normoglycaemia with insulin. Insulin degludec (IDeg) has an ultra‐long and stable glucose‐lowering effect, with low day‐to‐day variability. This pre‐planned meta‐analysis aimed to demonstrate the superiority of IDeg over insulin glargine (IGlar) in terms of fewer hypoglycaemic episodes at equivalent HbA1c in type 2 and type 1 diabetes mellitus (T2DM/T1DM).

• Publication year

  2012

• Venue

  Diabetes, obesity and metabolism

• Publication date

  2012-12-03

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/dom.12032PMID 23130654PMCID 3752969
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Insulin degludec compared with insulin glargine in insulin‐naïve patients with type 2 diabetes: A 26‐week, randomized, controlled, Pan‐Asian, treat‐to‐target trial

  2013cited by this paper
• Design of the Novel Protraction Mechanism of Insulin Degludec, an Ultra-long-Acting Basal Insulin

  2012cited by this paper
• Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial.

  2012cited by this paper
• 200 U/ml Insulin Degludec Improves Glycemic Control Similar to Insulin Glargine with a Low Risk of Hypoglycemia in Insulin-naïve People with Type 2 Diabetes

  2012cited by this paper
• A 1-year, randomized, treat-to-target trial (BEGIN Once Long)

  2012cited by this paper
• Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial.

  2012cited by this paper
• Insulin Degludec Allows for Flexible Daily Dosing in Type 1 Diabetes, Providing Equal Glycemic Control with Less Nocturnal Hypoglycemia than Insulin Glargine Over 52 Weeks

  2012cited by this paper
• Ultra‐long‐acting insulin degludec has a flat and stable glucose‐lowering effect in type 2 diabetes

  2012cited by this paper
• Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady‐state conditions in type 1 diabetes

  2012cited by this paper
• Hypoglycemia, Treatment Discontinuation, and Costs in Patients with Type 2 Diabetes Mellitus on Oral Antidiabetic Drugs

  2012cited by this paper
• Insulin Degludec in Type 1 Diabetes

  2011cited by this paper
• Hypoglycemia Rates with Basal Insulin Analogs

  2011cited by this paper
• Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial.

  2011cited by this paper
• The impact of non-severe hypoglycemic events on work productivity and diabetes management.

  2011cited by this paper
• A randomized controlled trial of a new-generation ultra-long-acting insulin compared with insulin glargine

  2011cited by this paper
• The Gains from Delegation Revisited: Price-Level Targeting, Speed-Limit and Interest Rate Smoothing Policies

  2011cited by this paper
• A 24-Week, Randomized, Treat-to-Target Trial Comparing Initiation of Insulin Glargine Once-Daily With Insulin Detemir Twice-Daily in Patients With Type 2 Diabetes Inadequately Controlled on Oral Glucose-Lowering Drugs

  2010cited by this paper
• Insulin Therapy for Type 2 Diabetes

  2009cited by this paper
• Comparison of insulin detemir and insulin glargine in a basal-bolus regimen, with insulin aspart as the mealtime insulin, in patients with type 1 diabetes: a 52-week, multinational, randomized, open-label, parallel-group, treat-to-target noninferiority trial.

  2009cited by this paper
• A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes.

  2008cited by this paper
• The Barrier of Hypoglycemia in Diabetes

  2008cited by this paper
• Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus.

  2007influential reference
• A 26-Week, Randomized, Parallel, Treat-to-Target Trial Comparing Insulin Detemir With NPH Insulin as Add-On Therapy to Oral Glucose-Lowering Drugs in Insulin-Naïve People With Type 2 Diabetes

  2007cited by this paper
• Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes.

  2005cited by this paper
• The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients.

  2003cited by this paper
• Hypoglycaemia: The limiting factor in the glycaemic management of Type I and Type II Diabetes*

  2002cited by this paper
• Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.

  1999cited by this paper
• Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)

  1998cited by this paper
• Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

  1998cited by this paper
• Relationship between lactate dehydrogenase and myeloperoxidase levels in human gingival crevicular fluid and clinical and microbial measurements.

  1988cited by this paper

• Perioperative Medication Management for Patients with Diabetes

  2026cites this paper
• Thrice-Weekly Insulin Degludec Versus Once-Daily Insulin Glargine in Insulin-Naïve Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis.

  2025cites this paper
• An Overview of Currently Available Injectable Therapies in Diabetes: A Guide to Practitioners

  2025cites this paper
• Advancement of artificial intelligence based treatment strategy in type 2 diabetes: A critical update

  2025cites this paper
• Current treatment for diabetes: a holistic approach.

  2025cites this paper
• Diabetes in Pregnancy and Major New Advances in Diabetes Care Using Long and Ultra-Long Acting Insulins.

  2025cites this paper
• An overview of randomized clinical trials of fixed‐ratio combinations of basal insulin plus GLP‐1RA (injectable therapy): Lessons for advancing therapy in people with type 2 diabetes

  2025influential citation
• Healthcare Resource Utilization and Costs Related to Falls and Fractures Among People With Type 2 Diabetes Receiving Basal Insulin: The FRAGILE Study

  2025cites this paper
• Once-weekly insulin icodec versus once-daily long-acting insulins for type 2 diabetes mellitus: Systematic review and meta-analysis

  2024cites this paper
• Once‐weekly insulin icodec compared with daily basal insulin analogues in type 2 diabetes: Participant‐level meta‐analysis of the ONWARDS 1–5 trials

  2024cites this paper
• The Basis for Weekly Insulin Therapy: Evolving Evidence With Insulin Icodec and Insulin Efsitora Alfa

  2024cites this paper
• Insulin Analogs and the Mode of Insulin Delivery: Recent Advances and Challenges.

  2024cites this paper
• Pharmacologic Glycemic Management of Type 2 Diabetes in Adults---2024 Update.

  2024cites this paper
• Study on bioequivalence and influence of obesity-related indicators on pharmacokinetics and pharmacodynamics for insulin degludec in healthy subjects

  2024cites this paper
• Efficacy and safety of insulin degludec biosimilar B01411 versus originator insulin degludec in Chinese patients with type 2 diabetes inadequately controlled on oral antidiabetic drugs: a multicenter, randomized, open-label, phase 3 study

  2024cites this paper
• Insulin's Legacy: A Century of Breakthroughs and Innovation.

  2024cites this paper
• Insulin Degludec in People with Type 2 Diabetes in China: A Non-interventional, Retrospective Chart Review Study (CN-TREAT)

  2024cites this paper
• [Unmet needs in the therapy of type 2 diabetes mellitus. How can barriers to insulin therapy be overcome?]

  2023cites this paper
• Commercially available injectables in diabetes – Insulin, incretins, and more

  2023cites this paper
• Hypoglycemia in Adults.

  2023cites this paper
• Weekly Icodec versus Daily Glargine U100 in Type 2 Diabetes without Previous Insulin.

  2023cites this paper
• ONWARDS and upwards for basal insulin.

  2023cites this paper
• Once-Weekly Insulin Icodec vs Once-Daily Insulin Degludec in Adults With Insulin-Naive Type 2 Diabetes: The ONWARDS 3 Randomized Clinical Trial.

  2023cites this paper
• Weekly Icodec versus Daily Glargine U100 in Type 2 Diabetes without Previous Insulin.

  2023cites this paper
• The use of long-acting insulin degludec in adult patients with type 2 diabetes mellitus in real clinical practice in Russia

  2023cites this paper
• Injectable Systems for Long-lasting Insulin Therapy.

  2023cites this paper
• Análogos de la insulina. ¿Cuál es su lugar en la terapéutica?

  2022cites this paper
• Effect of the Concomitant Use of Subcutaneous Basal Insulin and Intravenous Insulin Infusion in the Treatment of Severe Hyperglycemic Patients

  2022cites this paper
• Insulin: evolution of insulin formulations and their application in clinical practice over 100 years

  2022cites this paper
• Glycaemic Control in People with Type 2 Diabetes Treated with Insulin Degludec: A Real-World, Prospective Non-interventional Study—UPDATES Saudi Arabia

  2022cites this paper
• One-year safety and effectiveness of insulin degludec in patients with diabetes mellitus in routine clinical practice in India—TRUST (Tresiba real-world use study)

  2022cites this paper
• A glorious past, dynamic present and a promising future: Insulin at 100

  2022cites this paper
• Tratamiento de la diabetes mellitus tipo 2 en personas de edad avanzada o frágiles. Actualización 2022 del documento de consenso 2018 «Tratamiento de la diabetes mellitus tipo 2 en el paciente anciano»

  2022cites this paper
• Endocrinología, Diabetes y Nutrición: resumen del año 2022

  2022cites this paper
• Real-World Impact of Switching From Insulin Glargine (Lantus®) to Basaglar® and Potential Cost Saving in a Large Public Healthcare System in Saudi Arabia

  2022cites this paper
• The Cost-Effectiveness Of Intermediate-Acting, Long-Acting, Ultralong-Acting, and Biosimilar Insulins for Type 1 Diabetes Mellitus: A Systematic Review.

  2022cites this paper
• Hypoglycaemic therapy in frail older people with type 2 diabetes mellitus—a choice determined by metabolic phenotype

  2022cites this paper
• One hundred years of insulin therapy

  2021cites this paper
• Randomised Controlled Trials in Diabetes Research: A Pathway to Interpreting Published Results

  2021cites this paper
• Effect of insulin degludec versus insulin glargine U100 on time in range: SWITCH PRO, a crossover study of basal insulin‐treated adults with type 2 diabetes and risk factors for hypoglycaemia

  2021influential citation
• Synthetic long-acting insulin analogs for the management of type 1 diabetes: an update

  2021cites this paper
• Ultralong Analogue Insulin Degludec in Type 1 Diabetes : Reduction of Hypoglycemic Events

  2021cites this paper
• Insulin glargine 300 units/mL for the treatment of individuals with type 2 diabetes in the real world: A review of the DELIVER programme

  2021cites this paper
• Safety and efficacy of long-acting insulins (degludec and glargine) among type 2 diabetic Asian Population: A Systematic Review and Meta-Analysis.

  2021cites this paper
• Use of Insulin Degludec/Insulin Aspart in the Management of Diabetes Mellitus: Expert Panel Recommendations on Appropriate Practice Patterns

  2021cites this paper
• Efficacy and safety among second-generation and other basal insulins in adult patients with type 1 diabetes: a systematic review and network meta-analysis

  2021cites this paper
• E cacy and Safety Among Second-Generation and Other Basal Insulins in Adult Patients with Type 1 Diabetes: A Systematic Review and Network Meta- Analysis

  2021influential citation
• Travelling Across Time Zones With Type 1 Diabetes: A Pilot Study Comparing Insulin Degludec With Insulin Glargine U100.

  2021cites this paper
• Hospitalization costs with degludec versus glargine U100 for patients with type 2 diabetes at high cardiovascular risk: Canadian costs applied to SAEs from a randomized outcomes trial

  2021cites this paper
• Degludec hospital trial: A randomized controlled trial comparing insulin degludec U100 and glargine U100 for the inpatient management of patients with type 2 diabetes

  2021cites this paper
• Basal Insulin degludec and GLycemic control ComparEd to Aspart via insulin Pump in type 1 diabetes (BIGLEAP): a single-center, open-label, randomized, crossover trial.

  2021cites this paper
• Relationship between the early initiation of insulin treatment and diabetic complications in patients newly diagnosed with type 2 diabetes mellitus in Korea: A nationwide cohort study

  2021cites this paper
• New Horizons: Next-Generation Insulin Analogs: Structural Principles and Clinical Goals.

  2021cites this paper
• Evaluating the Effectiveness of Switching to Insulin Degludec from Other Basal Insulins in a Real-World Canadian Population with Type 1 or Type 2 Diabetes: The CAN-TREAT Study

  2021cites this paper
• An update on the safety of insulin-GLP-1 receptor agonist combinations in type 2 diabetes mellitus

  2021cites this paper
• Basal weekly insulins: the way of the future!

  2021cites this paper
• Trends in basal insulin prescribing in older adults with chronic kidney disease in Ontario, Canada: A population‐based analysis from 2010 to 2020

  2021cites this paper
• The Value of Insulin Degludec in Frail Older Adults with Type 2 Diabetes

  2021cites this paper
• Si l'ère des insulines semi-synthétiques et biosynthétiques nous était contée

  2021cites this paper
• Comparison of treatment with insulin degludec and glargine U100 in patients with type 1 diabetes prone to nocturnal severe hypoglycaemia: The HypoDeg randomized, controlled, open‐label, crossover trial

  2021cites this paper
• Significance of Glycemic Variability in Diabetes Mellitus

  2021cites this paper
• Safety and Efficacy of Long-Acting Insulins Degludec and Glargine Among Asian Patients With Type 2 Diabetes Mellitus: A Meta-Analysis

  2021cites this paper
• A Randomized, Open-Label Comparison of Once-Weekly Insulin Icodec Titration Strategies Versus Once-Daily Insulin Glargine U100

  2021cites this paper
• Cost-effectiveness of switching to insulin degludec from other basal insulins in real-world clinical practice in Italy

  2020cites this paper
• COST-EFFECTIVENESS ANALYSIS OF IDEG VS IGLAR U100 IN PATIENTS WITH TYPE 1 AND TYPE 2 DIABETES IN PORTUGAL: EVIDENCE FROM THE SWITCH 1&2 TRIALS

  2020cites this paper
• Pharmacokinetic and Pharmacodynamic Head-to-Head Comparison of Clinical, Equivalent Doses of Insulin Glargine 300 units · mL-1 and Insulin Degludec 100 units · mL-1 in Type 1 Diabetes.

  2020cites this paper
• DEGLUDEC INSULIN IN TYPE 1 DIABETIC PATIENTS: 18 MONTHS OF OBSERVATION

  2020influential citation
• Considerations for Insulin-Treated Type 2 Diabetes Patients During Hospitalization: A Narrative Review of What We Need to Know in the Age of Second-Generation Basal Insulin Analogs

  2020cites this paper
• Reduced Rates of Hypoglycemia in Type 1 or Type 2 Diabetes After Switching to Insulin Degludec: Results from the Italian Cohort of the ReFLeCT Study

  2020cites this paper
• Pharmacologic Glycemic Management of Type 2 Diabetes in Adults: 2020 Update.

  2020cites this paper
• The Safety and Efficacy of Second-Generation Basal Insulin Analogues in Adults with Type 2 Diabetes at Risk of Hypoglycemia and Use in Other Special Populations: A Narrative Review

  2020cites this paper
• Are newer insulin analogues better for people with Type 1 diabetes?

  2020cites this paper
• Estrategia terapéutica en el paciente diabético (III). Insulinoterapia

  2020cites this paper
• Comparison of Second-Generation Basal Insulin Analogs: A Review of the Evidence from Continuous Glucose Monitoring

  2020influential citation
• Switching to Degludec is Associated with Reduced Hypoglycaemia, Irrespective of Definition Used or Patient Characteristics: Secondary Analysis of the ReFLeCT Prospective, Observational Study

  2020cites this paper
• Understanding the Clinical Profile of Insulin Degludec, the Latest Basal Insulin Approved for Use in Canada: a Narrative Review

  2020cites this paper
• Second‐generation basal insulins to initiate insulin therapy in type 2 diabetes: A need for clinical evidence before incurring increased costs

  2020cites this paper
• Once-Weekly Insulin for Type 2 Diabetes without Previous Insulin Treatment.

  2020cites this paper
• The Clinical Role of Insulin Degludec/Insulin Aspart in Type 2 Diabetes: An Empirical Perspective from Experience in Australia

  2020cites this paper
• Risk factors for kidney disorders in patients with type 2 diabetes at high cardiovascular risk: An exploratory analysis (DEVOTE 12)

  2020cites this paper
• Insulin Therapy in Type 2 Diabetes.

  2020cites this paper
• In Silico Head-to-Head Comparison of Insulin Glargine 300 U/mL and Insulin Degludec 100 U/mL in Type 1 Diabetes

  2020cites this paper
• A greater proportion of participants with type 2 diabetes achieve treatment targets with insulin degludec/liraglutide versus insulin glargine 100 units/mL at 26 weeks: DUAL VIII, a randomized trial designed to resemble clinical practice

  2020cites this paper
• Insulin glargine 300 U/mL and insulin degludec: A review of the current evidence comparing these two second‐generation basal insulin analogues

  2020influential citation
• The relationship between HbA1c and hypoglycaemia in patients with diabetes treated with insulin degludec versus insulin glargine 100 units/mL

  2020cites this paper
• Clinical Considerations When Initiating and Titrating Insulin Degludec/Liraglutide (IDegLira) in People with Type 2 Diabetes

  2020cites this paper
• Risk of hypoglycaemia with insulin degludec versus insulin glargine U300 in insulin-treated patients with type 2 diabetes: the randomised, head-to-head CONCLUDE trial

  2020cites this paper
• Management of patients with diabetes and obesity in the COVID-19 era: Experiences and learnings from South and East Europe, the Middle East, and Africa

  2020cites this paper
• Cost analysis of insulin degludec in comparison with insulin detemir in treatment of children and adolescents with type 1 diabetes in the UK

  2019cites this paper
• Risk of Hyperglycemia and Hypoglycemia in Patients with Acute Ischemic Stroke Based on Continuous Glucose Monitoring.

  2019cites this paper
• Efficacy and safety of insulin degludec U 100 and insulin glargine U 100 in combination with mealtime bolus insulin in hospitalized patients with type 2 diabetes : an open-label , randomized controlled study

  2019cites this paper
• Rates of Hypoglycemia Predicted in Patients with Type 2 Diabetes on Insulin Glargine 300 U/ml Versus First- and Second-Generation Basal Insulin Analogs: The Real-World LIGHTNING Study

  2019influential citation
• What is innovation in the area of medicines? The example of insulin and diabetes

  2019cites this paper
• Comparison of the efficacy and safety of once-daily insulin degludec/insulin aspart (IDegAsp) and long-acting second-generation basal insulin (insulin degludec and insulin glargine 300 units/mL) in insulin-naïve Japanese adults with type 2 diabetes: a pilot, randomized, controlled study.

  2019cites this paper
• The effect of insulin degludec on risk of symptomatic nocturnal hypoglycaemia in adults with type 1 diabetes and high risk of nocturnal severe hypoglycaemia (the HypoDeg trial): study rationale and design

  2019cites this paper
• Switching to Degludec From Other Basal Insulins Is Associated With Reduced Hypoglycemia Rates: A Prospective Study

  2019cites this paper
• Pharmacokinetic and pharmacodynamic differences of new generation, longer-acting basal insulins: potential implications for clinical practice in type 2 diabetes

  2019cites this paper
• L'efficacité et la sécurité cardiovasculaire de l’insuline dégludec comparativement à l’insuline glargine pour les patients souffrant de diabète de type 2 : Étude DEVOTE

  2019cites this paper
• Are newer insulins always the better option?

  2019cites this paper
• Clinical Use of Degludec in Children and Adolescents with T1D: A Narrative Review with Fictionalized Case Reports

  2019cites this paper